Neural Mechanisms and Psychology of Psychedelic Ego Dissolution
Neuroimaging studies of psychedelics have advanced our understanding of hierarchical brain organization and the mechanisms underlying their subjective and therapeutic effects. The primary mechanism of action of classic psychedelics is binding to serotonergic 5-HT2A receptors. Agonist activity at the...
Saved in:
| Published in: | Pharmacological reviews Vol. 74; no. 4; p. 876 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
01.10.2022
|
| Subjects: | |
| ISSN: | 1521-0081, 1521-0081 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Neuroimaging studies of psychedelics have advanced our understanding of hierarchical brain organization and the mechanisms underlying their subjective and therapeutic effects. The primary mechanism of action of classic psychedelics is binding to serotonergic 5-HT2A receptors. Agonist activity at these receptors leads to neuromodulatory changes in synaptic efficacy that can have a profound effect on hierarchical message-passing in the brain. Here, we review the cognitive and neuroimaging evidence for the effects of psychedelics: in particular, their influence on selfhood and subject-object boundaries-known as ego
-surmised to underwrite their subjective and therapeutic effects. Agonism of 5-HT2A receptors, located at the apex of the cortical hierarchy, may have a particularly powerful effect on sentience and consciousness. These effects can endure well after the pharmacological half-life, suggesting that psychedelics may have effects on neural plasticity that may play a role in their therapeutic efficacy. Psychologically, this may be accompanied by a disarming of ego
that increases the repertoire of perceptual hypotheses and affords alternate pathways for thought and behavior, including those that undergird selfhood. We consider the interaction between serotonergic neuromodulation and sentience through the lens of hierarchical predictive coding, which speaks to the value of psychedelics in understanding how we make sense of the world and specific predictions about effective connectivity in cortical hierarchies that can be tested using functional neuroimaging. SIGNIFICANCE STATEMENT: Classic psychedelics bind to serotonergic 5-HT2A receptors. Their agonist activity at these receptors leads to neuromodulatory changes in synaptic efficacy, resulting in a profound effect on information processing in the brain. Here, we synthesize an abundance of brain imaging research with pharmacological and psychological interpretations informed by the framework of predictive coding. Moreover, predictive coding is suggested to offer more sophisticated interpretations of neuroimaging findings by bridging the role between the 5-HT2A receptors and large-scale brain networks. |
|---|---|
| AbstractList | Neuroimaging studies of psychedelics have advanced our understanding of hierarchical brain organization and the mechanisms underlying their subjective and therapeutic effects. The primary mechanism of action of classic psychedelics is binding to serotonergic 5-HT2A receptors. Agonist activity at these receptors leads to neuromodulatory changes in synaptic efficacy that can have a profound effect on hierarchical message-passing in the brain. Here, we review the cognitive and neuroimaging evidence for the effects of psychedelics: in particular, their influence on selfhood and subject-object boundaries-known as ego
-surmised to underwrite their subjective and therapeutic effects. Agonism of 5-HT2A receptors, located at the apex of the cortical hierarchy, may have a particularly powerful effect on sentience and consciousness. These effects can endure well after the pharmacological half-life, suggesting that psychedelics may have effects on neural plasticity that may play a role in their therapeutic efficacy. Psychologically, this may be accompanied by a disarming of ego
that increases the repertoire of perceptual hypotheses and affords alternate pathways for thought and behavior, including those that undergird selfhood. We consider the interaction between serotonergic neuromodulation and sentience through the lens of hierarchical predictive coding, which speaks to the value of psychedelics in understanding how we make sense of the world and specific predictions about effective connectivity in cortical hierarchies that can be tested using functional neuroimaging. SIGNIFICANCE STATEMENT: Classic psychedelics bind to serotonergic 5-HT2A receptors. Their agonist activity at these receptors leads to neuromodulatory changes in synaptic efficacy, resulting in a profound effect on information processing in the brain. Here, we synthesize an abundance of brain imaging research with pharmacological and psychological interpretations informed by the framework of predictive coding. Moreover, predictive coding is suggested to offer more sophisticated interpretations of neuroimaging findings by bridging the role between the 5-HT2A receptors and large-scale brain networks. Neuroimaging studies of psychedelics have advanced our understanding of hierarchical brain organization and the mechanisms underlying their subjective and therapeutic effects. The primary mechanism of action of classic psychedelics is binding to serotonergic 5-HT2A receptors. Agonist activity at these receptors leads to neuromodulatory changes in synaptic efficacy that can have a profound effect on hierarchical message-passing in the brain. Here, we review the cognitive and neuroimaging evidence for the effects of psychedelics: in particular, their influence on selfhood and subject-object boundaries-known as ego dissolution-surmised to underwrite their subjective and therapeutic effects. Agonism of 5-HT2A receptors, located at the apex of the cortical hierarchy, may have a particularly powerful effect on sentience and consciousness. These effects can endure well after the pharmacological half-life, suggesting that psychedelics may have effects on neural plasticity that may play a role in their therapeutic efficacy. Psychologically, this may be accompanied by a disarming of ego resistance that increases the repertoire of perceptual hypotheses and affords alternate pathways for thought and behavior, including those that undergird selfhood. We consider the interaction between serotonergic neuromodulation and sentience through the lens of hierarchical predictive coding, which speaks to the value of psychedelics in understanding how we make sense of the world and specific predictions about effective connectivity in cortical hierarchies that can be tested using functional neuroimaging. SIGNIFICANCE STATEMENT: Classic psychedelics bind to serotonergic 5-HT2A receptors. Their agonist activity at these receptors leads to neuromodulatory changes in synaptic efficacy, resulting in a profound effect on information processing in the brain. Here, we synthesize an abundance of brain imaging research with pharmacological and psychological interpretations informed by the framework of predictive coding. Moreover, predictive coding is suggested to offer more sophisticated interpretations of neuroimaging findings by bridging the role between the 5-HT2A receptors and large-scale brain networks.Neuroimaging studies of psychedelics have advanced our understanding of hierarchical brain organization and the mechanisms underlying their subjective and therapeutic effects. The primary mechanism of action of classic psychedelics is binding to serotonergic 5-HT2A receptors. Agonist activity at these receptors leads to neuromodulatory changes in synaptic efficacy that can have a profound effect on hierarchical message-passing in the brain. Here, we review the cognitive and neuroimaging evidence for the effects of psychedelics: in particular, their influence on selfhood and subject-object boundaries-known as ego dissolution-surmised to underwrite their subjective and therapeutic effects. Agonism of 5-HT2A receptors, located at the apex of the cortical hierarchy, may have a particularly powerful effect on sentience and consciousness. These effects can endure well after the pharmacological half-life, suggesting that psychedelics may have effects on neural plasticity that may play a role in their therapeutic efficacy. Psychologically, this may be accompanied by a disarming of ego resistance that increases the repertoire of perceptual hypotheses and affords alternate pathways for thought and behavior, including those that undergird selfhood. We consider the interaction between serotonergic neuromodulation and sentience through the lens of hierarchical predictive coding, which speaks to the value of psychedelics in understanding how we make sense of the world and specific predictions about effective connectivity in cortical hierarchies that can be tested using functional neuroimaging. SIGNIFICANCE STATEMENT: Classic psychedelics bind to serotonergic 5-HT2A receptors. Their agonist activity at these receptors leads to neuromodulatory changes in synaptic efficacy, resulting in a profound effect on information processing in the brain. Here, we synthesize an abundance of brain imaging research with pharmacological and psychological interpretations informed by the framework of predictive coding. Moreover, predictive coding is suggested to offer more sophisticated interpretations of neuroimaging findings by bridging the role between the 5-HT2A receptors and large-scale brain networks. |
| Author | Egan, Gary F Friston, Karl J Razi, Adeel Stoliker, Devon |
| Author_xml | – sequence: 1 givenname: Devon surname: Stoliker fullname: Stoliker, Devon organization: Turner Institute for Brain and Mental Health (D.S., G.F.E., A.R.) and Monash Biomedical Imaging (G.F.E., A.R.), Monash University, Clayton, Victoria, Australia; Wellcome Centre for Human Neuroimaging, UCL, London, United Kingdom (K.J.F., A.R.); and CIFAR Azrieli Global Scholar, CIFAR, Toronto, Canada (A.R.) – sequence: 2 givenname: Gary F surname: Egan fullname: Egan, Gary F organization: Turner Institute for Brain and Mental Health (D.S., G.F.E., A.R.) and Monash Biomedical Imaging (G.F.E., A.R.), Monash University, Clayton, Victoria, Australia; Wellcome Centre for Human Neuroimaging, UCL, London, United Kingdom (K.J.F., A.R.); and CIFAR Azrieli Global Scholar, CIFAR, Toronto, Canada (A.R.) – sequence: 3 givenname: Karl J surname: Friston fullname: Friston, Karl J organization: Turner Institute for Brain and Mental Health (D.S., G.F.E., A.R.) and Monash Biomedical Imaging (G.F.E., A.R.), Monash University, Clayton, Victoria, Australia; Wellcome Centre for Human Neuroimaging, UCL, London, United Kingdom (K.J.F., A.R.); and CIFAR Azrieli Global Scholar, CIFAR, Toronto, Canada (A.R.) – sequence: 4 givenname: Adeel orcidid: 0000-0002-0779-9439 surname: Razi fullname: Razi, Adeel email: Adeelr.Razi@monash.edu organization: Turner Institute for Brain and Mental Health (D.S., G.F.E., A.R.) and Monash Biomedical Imaging (G.F.E., A.R.), Monash University, Clayton, Victoria, Australia; Wellcome Centre for Human Neuroimaging, UCL, London, United Kingdom (K.J.F., A.R.); and CIFAR Azrieli Global Scholar, CIFAR, Toronto, Canada (A.R.) Adeelr.Razi@monash.edu |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36786290$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNj0tLw0AUhQep2If-AkGydJM692ZmMlmJtPUB9bHQdZhX2sgkUzONkH-v0Aquznfg48CZklEbWkfIJdA5ALKb3VZ1Tee-54Awp5RyKk_IBDhCSqmE0T8ek2mMn5QC45KfkXEmcimwoBNy--L6Tvnk2ZmtauvYxES1NnmLg9kGHzZDEqpDc9b52iSrTUiWdYzB9_s6tOfktFI-uotjzsjH_ep98ZiuXx-eFnfr1DDK9qlGURUsY1oJytFIw5XImZYIecUyi1ob4ZBZnQO3aAC5ZrZAy6m1ioPCGbk-7O668NW7uC-bOhrnvWpd6GOJeS44FFzIX_XqqPa6cbbcdXWjuqH8O40_ksZcUQ |
| CitedBy_id | crossref_primary_10_1016_j_isci_2024_109686 crossref_primary_10_1162_netn_a_00408 crossref_primary_10_1007_s12152_024_09571_4 crossref_primary_10_1016_j_neubiorev_2025_106319 crossref_primary_10_1016_j_neubiorev_2025_106239 crossref_primary_10_1016_j_biopsych_2024_01_002 crossref_primary_10_1016_j_neuroimage_2025_121247 crossref_primary_10_3389_fpsyg_2025_1580663 crossref_primary_10_3390_biomedicines13082025 crossref_primary_10_3758_s13421_024_01575_y crossref_primary_10_1016_j_concog_2023_103536 crossref_primary_10_1016_j_concog_2023_103474 crossref_primary_10_1089_psymed_2024_0009 crossref_primary_10_1038_s41398_023_02691_0 crossref_primary_10_1111_psyp_14583 crossref_primary_10_3389_fpsyt_2023_1286941 crossref_primary_10_1016_j_bpsc_2023_07_010 crossref_primary_10_1080_09540261_2025_2478907 crossref_primary_10_1007_s11910_024_01353_y crossref_primary_10_1016_j_neuropsychologia_2025_109238 crossref_primary_10_1093_ijnp_pyac074 crossref_primary_10_1111_adb_13386 crossref_primary_10_1038_s41380_024_02632_3 crossref_primary_10_1016_j_pnpbp_2025_111333 crossref_primary_10_1038_s41398_024_03029_0 crossref_primary_10_3390_brainsci15020117 crossref_primary_10_1093_ijnp_pyaf010 crossref_primary_10_1177_02698811231216322 crossref_primary_10_3389_fpsyg_2025_1455902 crossref_primary_10_3390_molecules29050964 crossref_primary_10_3389_fnins_2023_1232459 crossref_primary_10_3389_fnins_2023_1267611 crossref_primary_10_3389_fnins_2025_1606798 crossref_primary_10_54751_revistafoco_v18n5_175 crossref_primary_10_1016_j_euroneuro_2023_07_011 crossref_primary_10_1016_j_pnpbp_2025_111353 crossref_primary_10_1002_prp2_70097 crossref_primary_10_1007_s12671_023_02206_4 crossref_primary_10_1093_nc_niaf002 crossref_primary_10_3389_fnhum_2024_1495565 crossref_primary_10_3389_fpsyg_2025_1570049 crossref_primary_10_1093_nc_niae038 crossref_primary_10_3389_fpsyg_2025_1533055 crossref_primary_10_1016_j_biopsych_2022_07_013 crossref_primary_10_1016_j_bpsc_2024_02_001 crossref_primary_10_3389_fpsyt_2023_1287961 crossref_primary_10_1016_j_neubiorev_2024_105764 |
| ContentType | Journal Article |
| Copyright | Copyright © 2022 by The Author(s). |
| Copyright_xml | – notice: Copyright © 2022 by The Author(s). |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1124/pharmrev.121.000508 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1521-0081 |
| ExternalDocumentID | 36786290 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GrantInformation_xml | – fundername: Wellcome Trust grantid: 203147/Z/16/Z |
| GroupedDBID | --- -~X .55 .GJ 0R~ 123 18M 1KJ 2WC 3O- 4.4 53G 5RE 5VS AALRI AAXUO ABCQX ABJNI ABOCM ABSQV ACGFO ACGFS ADBBV ADCOW AENEX AERNN AETEA AFOSN ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD F5P F9R FDB GX1 H13 HZ~ INIJC KQ8 L7B LSO M41 MVM N4W N9A NPM O9- OK1 P2P RHI ROL RPT SJN TR2 W8F WOQ X7M YBU YHG YNH ZGI ZKB ZXP 7X8 |
| ID | FETCH-LOGICAL-c404t-b26f9434ba6052c8c5a674b8217f43d2bbc6e24db715d2c125b4d92d50dda51a2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 51 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000958588300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1521-0081 |
| IngestDate | Fri Sep 05 10:14:33 EDT 2025 Mon Jul 21 06:00:28 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| License | Copyright © 2022 by The Author(s). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c404t-b26f9434ba6052c8c5a674b8217f43d2bbc6e24db715d2c125b4d92d50dda51a2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-0779-9439 |
| OpenAccessLink | https://pharmrev.aspetjournals.org/content/pharmrev/74/4/876.full.pdf |
| PMID | 36786290 |
| PQID | 2776519568 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2776519568 pubmed_primary_36786290 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-10-00 20221001 |
| PublicationDateYYYYMMDD | 2022-10-01 |
| PublicationDate_xml | – month: 10 year: 2022 text: 2022-10-00 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Pharmacological reviews |
| PublicationTitleAlternate | Pharmacol Rev |
| PublicationYear | 2022 |
| SSID | ssj0014585 |
| Score | 2.5798652 |
| SecondaryResourceType | review_article |
| Snippet | Neuroimaging studies of psychedelics have advanced our understanding of hierarchical brain organization and the mechanisms underlying their subjective and... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 876 |
| SubjectTerms | Brain Consciousness Ego Hallucinogens - pharmacology Humans Solubility |
| Title | Neural Mechanisms and Psychology of Psychedelic Ego Dissolution |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/36786290 https://www.proquest.com/docview/2776519568 |
| Volume | 74 |
| WOSCitedRecordID | wos000958588300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7UevDi-1FfrCA9dTXZ7GaTUxFt8dKSQ4Xewj4loEk1Vei_dzdJm5MgeAnksBAmszPf7sx8HwC3AaHayDBEEY8lIiKKkaBEI6Mp08riE8p4JTbBJpNoNouT5sKtbNoqVzGxCtSqkO6O_B4zFtJquG0w_0BONcpVVxsJjU3QCSyUcS1dbNZWEQitJDldikIu9zWsQzal3c8dMbRTefGxf1exoES_Y8wq14z2_vuV-2C3QZnwoXaLA7Ch80PQS2qa6mUfTtupq7IPezBpCayXR2DgGDvs8rF2Y8FZ-V5Cniu4jpVLWJj6TSv9lkk4fC3gU7Z242PwMhpOH59RI7SAJPHIAgkcGscTJ7g93GAZScpDZv-bPa4YEigshAw1JkownyosLSYSRMVYUU8pTn2OT8BWXuT6DMDI8DjkFpV4TBHsBcLXhHAcy4AaL5KmC25WhkutI7vqBM918VWmrem64LS2fjqvGTfSwKbUEMfe-R9WX4Ad7EYUqoa7S9AxdhvrK7AtvxdZ-XldeYh9TpLxD66lxoY |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Neural+Mechanisms+and+Psychology+of+Psychedelic+Ego+Dissolution&rft.jtitle=Pharmacological+reviews&rft.au=Stoliker%2C+Devon&rft.au=Egan%2C+Gary+F&rft.au=Friston%2C+Karl+J&rft.au=Razi%2C+Adeel&rft.date=2022-10-01&rft.issn=1521-0081&rft.eissn=1521-0081&rft.volume=74&rft.issue=4&rft.spage=876&rft_id=info:doi/10.1124%2Fpharmrev.121.000508&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1521-0081&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1521-0081&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1521-0081&client=summon |